Anthem Biosciences Limited has announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported its highest revenue quarter ever in Q4FY26, driven by strong performance across its CRDMO and Specialty Ingredients segments.

Q4FY26 Financial Performance

For the quarter ended March 31, 2026, the company reported Revenue from Operations of ₹6,109 Mn, a growth of 26.4% compared to ₹4,832 Mn in the same period last year. On a sequential basis, revenue grew 44.4% from ₹4,232 Mn in Q3FY26. The CRDMO segment contributed ₹5,128 Mn, while Specialty Ingredients contributed ₹981 Mn. Profit After Tax (PAT) for the quarter surged 129.8% to ₹1,898 Mn from ₹826 Mn in Q4FY25. EBITDA stood at ₹3,184 Mn, with margins expanding to 48.1% from 40.38% in the same period last year.

The following table summarises Anthem Biosciences' key financial metrics for Q4FY26:

FY26 Annual Results

For the full financial year 2025-26, Revenue from Operations grew 15.2% to ₹21,243 Mn from ₹18,446 Mn in FY25. The CRDMO business recorded revenues of ₹17,727 Mn, and Specialty Ingredients recorded ₹3,516 Mn. PAT for the year increased 31.1% to ₹5,918 Mn, while EBITDA grew 30.8% to ₹9,896 Mn. The company maintained a healthy net cash position of ₹13,743 Mn as of March 31, 2026.

Operational Highlights

The company's EBITDA and PAT for the year grew by more than 30%, in line with its growth aspirations. Management attributed the performance to prudent cost management and a focus on long-term value creation. Profit before tax before exceptional items for FY26 stood at ₹8,486 Mn, with an exceptional item of ₹244 Mn recognized regarding the impact of new labour codes. For Q4FY26, the exceptional item was a credit of ₹10 Mn.

Anthem Biosciences continues to invest in expanding its manufacturing capacity, including a new greenfield facility at Harohalli, Bangalore, with a Phase I investment of ₹12,000 Mn. The company will conduct an earnings call on May 20, 2026, at 11:00 am IST to discuss the financial and business performance.

Anthem Biosciences Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone net profit of INR 6,705.64 million for the year, marking a 32.5% increase from INR 5,061.88 million in the previous year. Revenue from operations for the year stood at INR 20,893.12 million, compared to INR 18,406.49 million in FY25.

For the quarter ended March 31, 2026, the company recorded a standalone net profit of INR 2,116.65 million. Revenue from operations for the quarter was INR 5,825.01 million. The Board approved the audited standalone and consolidated financial results prepared in accordance with the Indian Accounting Standards (Ind-AS).

Dividend Declaration

The Board of Directors recommended a final dividend of INR 2.00 per equity share of face value INR 2.00 each for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting. The record date for the purpose of determining eligibility has been fixed as Friday, June 26, 2026.

Corporate Actions

The Board approved the allotment of 14,81,250 equity shares to eligible employees upon exercise of options under the Anthem Employee Stock Option Plan 2024. Consequently, the paid-up equity share capital has increased to INR 1,12,63,90,202. Additionally, the Board approved convening the 20th Annual General Meeting on Wednesday, July 22, 2026.

The Board also recommended the continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director and the re-appointment of Mr. Ravindra Chandrappa as Whole Time Director, subject to shareholder approval.

The statutory auditors, M/s. K. P. Rao & Co., issued an unmodified opinion on the audited standalone and consolidated financial results. The company also re-appointed M/s. BPU & Co. as internal auditors for the financial year 2026-2027.